以下为句子列表：
英文: Background Case reports and echocardiographic studies suggest that the ergot-derived dopamine agonists pergolide and cabergoline, used in the treatment of Parkinson's disease and the restless legs syndrome, may increase the risk of cardiac-valve regurgita
中文: 背景：病例报告和超声心动图研究提示，用于治疗帕金森病和不宁腿综合征的药物—麦角洐生物，多巴胺受体激动剂培高利特和卡麦角林，可能增加发生心脏瓣膜返流的风险。
更详细...
英文: Conclusions In this study, use of the dopamine agonists pergolide and cabergoline was associated with an increased risk of newly diagnosed cardiac-valve regurgitation.
中文: 结论：研究发现使用多巴胺受体激动剂培高利特和卡麦角林可增加新发生的心脏瓣膜返流的风险。
更详细...
英文: Conclusions The frequency of clinically important valve regurgitation was significantly increased in patients taking pergolide or cabergoline, but not in patients taking non–ergot-derived dopamine agonists, as compared with control subjects.
中文: 结论：与对照组相比，服用培高利特或者卡麦角林的患者临床上发生重要瓣膜返流的频率显著增加，但服用非麦角洐生的多巴胺受体激动剂的患者瓣膜返流的发生率却未增加。
更详细...
英文: Patients treated with ergot derivatives who had grade 3 to 4 regurgitation of any valve had received a significantly higher mean cumulative dose of pergolide or cabergoline than had patients with lower grades.
中文: 在服用麦角洐生物进行治疗的患者中，发生任何瓣膜3到4级返流的患者服用培高利特或卡麦角林的平均累积剂量显著高于瓣膜返流级别较低的患者。
更详细...
英文: Results Clinically important regurgitation (moderate to severe, grade 3 to 4) in any valve was found with significantly greater frequency in patients taking pergolide (23.4%) or cabergoline (28.6%) but not in patients taking non–ergot-derived dopamine ago
中文: 结果：与对照组相比（5.6%），服用培高利特（23.4%）或者卡麦角林的患者（28.6%），临床上发生重要的任何瓣膜的返流（中到重度，3级到4级）的频率显著升高，而服用非麦角洐生的多巴胺受体激动剂的患者（0%）瓣膜返流的发生率却未增加。
更详细...
|
